These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35585012)

  • 21. Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.
    Stapleton AL; Kimple AJ; Goralski JL; Nouraie SM; Branstetter BF; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Zemke AC
    J Cyst Fibros; 2022 Sep; 21(5):792-799. PubMed ID: 35300931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
    Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
    Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
    Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
    Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
    McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
    J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
    Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
    Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment.
    Bhaskaran D; Bateman K
    J Cyst Fibros; 2022 Nov; 21(6):1077-1079. PubMed ID: 35840534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.
    Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G
    J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
    McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
    J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.
    Savi D; Lucca F; Tridello G; Meneghelli I; Comello I; Tomezzoli S; Signorini M; Proietti E; Cucchetto G; Volpi S; Cipolli M
    Respir Med; 2023; 219():107406. PubMed ID: 37690570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
    Fajac I; Daines C; Durieu I; Goralski JL; Heijerman H; Knoop C; Majoor C; Bruinsma BG; Moskowitz S; Prieto-Centurion V; Van Brunt K; Zhang Y; Quittner A
    J Cyst Fibros; 2023 Jan; 22(1):119-123. PubMed ID: 36114142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy.
    Manciulli T; Bresci S; Mencarini J; Avarello A; Taccetti G; Terlizzi V
    Pediatr Pulmonol; 2023 Dec; 58(12):3626-3629. PubMed ID: 37750598
    [No Abstract]   [Full Text] [Related]  

  • 38. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
    Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
    J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation.
    Cheng A; Baker O; Hill U
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
    Wright BA; Ketchen NK; Rasmussen LN; Bartels AR; Singh SB
    Pediatr Pulmonol; 2022 Mar; 57(3):655-657. PubMed ID: 34859619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.